MK-8719, a Novel and Selective O-GlcNAcase Inhibitor That Reduces the Formation of Pathological Tau and Ameliorates Neurodegeneration in a Mouse Model of Tauopathy
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Deposition of hyperphosphorylated and aggregated tau protein in the central nervous system is characteristic of Alzheimer disease and other tauopathies. Tau is subject to O -linked N -acetylglucosamine ( O -GlcNAc) modification, and O -GlcNAcylation of tau has been shown to influence tau phosphorylation and aggregation. Inhibition of O -GlcNAcase (OGA), the enzyme that removes O -GlcNAc moieties, is a novel strategy to attenuate the formation of pathologic tau. Here we described the in vitro and in vivo pharmacological properties of a novel and selective OGA inhibitor, MK-8719. In vitro, this compound is a potent inhibitor of the human OGA enzyme with comparable activity against the corresponding enzymes from mouse, rat, and dog. In vivo, oral administration of MK-8719 elevates brain and peripheral blood mononuclear cell O -GlcNAc levels in a dose-dependent manner. In addition, positron emission tomography imaging studies demonstrate robust target engagement of MK-8719 in the brains of rats and rTg4510 mice. In the rTg4510 mouse model of human tauopathy, MK-8719 significantly increases brain O -GlcNAc levels and reduces pathologic tau. The reduction in tau pathology in rTg4510 mice is accompanied by attenuation of brain atrophy, including reduction of forebrain volume loss as revealed by volumetric magnetic resonance imaging analysis. These findings suggest that OGA inhibition may reduce tau pathology in tauopathies. However, since hundreds of O -GlcNAcylated proteins may be influenced by OGA inhibition, it will be critical to understand the physiologic and toxicological consequences of chronic O -GlcNAc elevation in vivo. SIGNIFICANCE STATEMENT MK-8719 is a novel, selective, and potent O -linked N- acetylglucosamine ( O -GlcNAc)-ase (OGA) inhibitor that inhibits OGA enzyme activity across multiple species with comparable in vitro potency. In vivo, MK-8719 elevates brain O -GlcNAc levels, reduces pathological tau, and ameliorates brain atrophy in the rTg4510 mouse model of tauopathy. These findings indicate that OGA inhibition may be a promising therapeutic strategy for the treatment of Alzheimer disease and other tauopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 4×
“Introduction Neurofibrillary tangles (NFTs), a pathologic hallmark of Alzheimer disease (AD), are mainly composed of intracellular hyperphosphorylated and aggregated microtubule-associated protein tau (Lee et al., 2001; Ballatore et al., 2007).”
BackgroundInfluentialTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“Introduction Neurofibrillary tangles (NFTs), a pathologic hallmark of Alzheimer disease (AD), are mainly composed of intracellular hyperphosphorylated and aggregated microtubule-associated protein tau (Lee et al., 2001; Ballatore et al., 2007).”
BackgroundThe clinical use of structural MRI in Alzheimer disease
Frisoni, G. B., Fox, N. C., Jack, C. R., Scheltens, P., & Thompson, P. M. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.215 · Cited by 2,113
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · cited 1×
“Impaired brain glucose metabolism has been observed in multiple neurodegenerative diseases, including AD, and may play a critical role in the pathogenesis of these diseases (Hoyer, 2000; Mosconi, 2005; Butterfield and Halliwell, 2019).”
BackgroundHansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 1×
“CSF total tau levels are elevated in AD patients, which may reflect axonal degeneration and tau pathology observed in AD brain (Hansson et al., 2006).”
BackgroundCycling of O-linked β-N-acetylglucosamine on nucleocytoplasmic proteins
Hart, G. W., Housley, M. P., & Slawson, C. (2007) · Nature · doi:10.1038/nature05815 · Cited by 1,418
Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD
Jack, C. R., Shiung, M. M., Gunter, J. L., O’Brien, P. C., Weigand, S. D., Knopman, D. S., Boeve, B. F., Ivnik, R. J., Smith, G. E., Cha, R. H., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000110315.26026.ef · Cited by 827
O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer's disease
Liu, F., Iqbal, K., Grundke-Iqbal, I., Hart, G. W., & Gong, C.-X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400348101 · Cited by 775 · cited 1×
“Consistent with these findings, O-GlcNAcylation levels are markedly reduced in AD brains as compared with healthy controls (Liu et al., 2004, 2009; Pinho et al., 2019).”
ResultA potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo
Yuzwa, S. A., Macauley, M. S., Heinonen, J. E., Shan, X., Dennis, R. J., He, Y., Whitworth, G. E., Stubbs, K. A., McEachern, E. J., Davies, G. J., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.96 · Cited by 717 · cited 3×
“…effects of OGA inhibition in animal models of tauopathy, including reduction of tau phosphorylation upon acute treatment with OGA inhibitors (Yuzwa et al., 2008; Yu et al., 2012; Graham et al., 2014), limiting the formation of tau aggregates (Yuzwa et al., 2012; Hastings et al., 2017) and…”
BackgroundSelf-citationRamsden, M., Kotilinek, L., Forster, C., Paulson, J., McGowan, E., SantaCruz, K., Guimaraes, A., Yue, M., Lewis, J., Carlson, G., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3279-05.2005 · Cited by 702 · cited 2×
“rTg4510 mice develop severe age-dependent atrophy and neuron loss in forebrain structures, the regions that overexpress human mutant P301L tau under the control of the calmodulin-dependent protein kinase II promoter (Ramsden et al., 2005; Santacruz et al., 2005; Yang et al., 2011; Wang et al., 2018).”
BackgroundIncreasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation
Yuzwa, S. A., Shan, X., Macauley, M. S., Clark, T., Skorobogatko, Y., Vosseller, K., & Vocadlo, D. J. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.797 · Cited by 611
Self-citationLiu, F., Shi, J., Tanimukai, H., Gu, J., Gu, J., Grundke-Iqbal, I., Iqbal, K., & Gong, C.-X. (2009) · Brain · doi:10.1093/brain/awp099 · Cited by 439 · cited 3×
“Consistent with these findings, O-GlcNAcylation levels are markedly reduced in AD brains as compared with healthy controls (Liu et al., 2004, 2009; Pinho et al., 2019).”
BackgroundResultHastings, N. B., Wang, X., Song, L., Butts, B. D., Grotz, D., Hargreaves, R., Fred Hess, J., Hong, K.-L. K., Huang, C. R.-R., Hyde, L., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0181-0 · Cited by 164 · cited 13×
“…80% knockdown of OGA protein in the OGA-inducible knockdown mice was only associated with 1.4-fold increase in brain O-GlcNAc, and 500 mg/kg dose of the potent OGA inhibitor Thiamet-G was needed to produce .3-fold brain O-GlcNAc elevation after a single oral administration (Hastings et al., 2017).”
BackgroundMethodResultSelf-citationWhole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study
Sluimer, J. D., Bouwman, F. H., Vrenken, H., Blankenstein, M. A., Barkhof, F., van der Flier, W. M., & Scheltens, P. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.016 · Cited by 106 · cited 2×
“In AD patients, vMRI studies have shown that the rates of brain atrophy in several structural measures, including hippocampus, entorhinal cortex, whole brain, and ventricle enlargement, correlate closely with changes in cognitive performance (Fox et al., 1999; Jack et al., 2004; Thompson et al., 2004; Schott et al., 2…”
BackgroundPinho, T. S., Correia, S. C., Perry, G., Ambrósio, A. F., & Moreira, P. I. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.10.037 · Cited by 70
Yang, D., Xie, Z., Stephenson, D., Morton, D., Hicks, C. D., Brown, T. M., Sriram, R., O'Neill, S., Raunig, D., & Bocan, T. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2010.10.067 · Cited by 64 · cited 2×
“rTg4510 mice develop severe age-dependent atrophy and neuron loss in forebrain structures, the regions that overexpress human mutant P301L tau under the control of the calmodulin-dependent protein kinase II promoter (Ramsden et al., 2005; Santacruz et al., 2005; Yang et al., 2011; Wang et al., 2018).”
Background
Cited by
Tauopathies: new perspectives and challenges
Zhang, Y., Wu, K.-M., Yang, L., Dong, Q., & Yu, J.-T. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00533-z · Cited by 323
Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers
Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119
Implications of Glycosylation in Alzheimer’s Disease
Haukedal, H., & Freude, K. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.625348 · Cited by 114
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies
Permanne, B., Sand, A., Ousson, S., Nény, M., Hantson, J., Schubert, R., Wiessner, C., Quattropani, A., & Beher, D. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00057 · Cited by 82
Chen, L., Jiang, H., Licinio, J., & Wu, H. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02943-z · Cited by 33
Metadata
- Authors
- Wang, X., Li, W., Marcus, J., Pearson, M., Song, L., Smith, K., Terracina, G., Lee, J., Hong, K.-L. K., Lu, S. X., Hyde, L., Chen, S.-C., Kinsley, D., Melchor, J. P., Rubins, D. J., Meng, X., Hostetler, E., Sur, C., Zhang, L., Schachter, J. B., Hess, J. F., Selnick, H. G., Vocadlo, D. J., McEachern, E. J., Uslaner, J. M., Duffy, J. L., & Smith, S. M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2020-08
- Volume
- 374
- Issue
- 2
- Pages
- 252-263
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W3031176037
- Cited by
- 79
- References
- 17
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.